Assessment of Proximal Femur Bone Density and Geometry by Dxa in Japanese Patients Treated with Risedronate

Hip structure analysis (HSA) and advanced hip assessment (AHA) can be used to evaluate proximal femur geometry based on dual energy X-ray absorptiometry scans of the hip. The purpose of this review was to reveal the effects of 1-year risedronate therapy on proximal femur bone mineral density (BMD) and geometry in Japanese patients with an increased risk for fractures. The relevant literature was searched using PubMed and two available clinical practice-based observational studies were identified. The HSA study revealed that the BMD increased at the intertrochanter and shaft, the cross-sectional area (CSA) and section modulus increased at the narrow neck, intertrochanteric, and shaft and the buckling ratio decreased at the intertrochanteric. The increase in section modulus was greater than the increase in BMD. The AHA study revealed that the total hip and femoral neck BMD, CSA, cross-sectional moment of inertia (CSMI), and femoral strength index (FSI) of the proximal femur increased. The increases in CSMI, CSA, and FSI were greater than the increases in femoral neck and total hip BMD. These results suggested beneficial effects of risedronate therapy on proximal femur geometry assessed by HSA and AHA in Japanese patients with an increased risk for fractures, indicating positive effects of risedronate on the structural properties in terms of bone quality.